Triple-negative breast cancer (TNBC) accounts for 10–20% of invasive BC cases and is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [3]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.